Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.70 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.71 +0.01 (0.59%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 181 - 200 ( 393 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sotagliflozin''s Emerging Clinical Profile Strengthened by Positive InTandem4 Phase 2 Results, In Our View; Reiterate OUTPERFORM and $33 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Physician Feedback Leaves Us More Confident in Telotristat Prospects in Europe
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Two-Part Story With Upside Prospects; Initiating With a Buy and a $26 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PDUFA Date Extension for Telotristat Etiprate Has No Impact on Our View; Still Anticipate First Pass Approval; Reiterate OUTPERFORM and $33 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sotagliflozin Achieves Primary Endpoint in First T1D Phase III Trial; Reiterate OUTPERFORM and Raising PT to $33
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Update; Several Regulatory and Late-Stage Clinical Catalysts Expected in H2; Maintain OUTPERFORM and Increasing PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L